Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. The DRTS news feed highlights the company’s clinical progress, regulatory interactions, manufacturing milestones, and financial updates related to this technology.
Recent news has focused on Alpha Tau’s expanding clinical program. The company has reported final results from a first-in-human pancreatic ductal adenocarcinoma study in Montreal, including disease control and response rates, and is running the IMPACT multi-center pilot trial in the United States combining Alpha DaRT with chemotherapy in newly diagnosed unresectable or metastatic pancreatic cancer. News items also cover pilot studies in recurrent glioblastoma multiforme, including the first reported Alpha DaRT treatment in the brain, as well as FDA-approved trials in locally recurrent prostate cancer.
Regulatory and pre-market developments are another frequent theme. Alpha Tau has announced submission of the first module of its pre-market approval application to the U.S. FDA for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, under a modular PMA framework. The company also reports on Breakthrough Device Designations, participation in the FDA’s Total Product Life Cycle Advisory Program, and marketing authorization processes in other regions.
Operational and corporate updates appear regularly, including receipt of a radioactive material license for the company’s manufacturing facility in New Hampshire, participation in major healthcare and investor conferences, and periodic financial results with corporate commentary. Investors and observers can use the DRTS news page to follow key milestones in Alpha Tau’s efforts to advance Alpha DaRT through clinical development, regulatory review, and preparation for potential commercialization.
Alpha Tau (Nasdaq: DRTS) reported pooled results from two first-in-human Alpha DaRT pancreatic cancer trials presented at DDW 2026. Across 19 evaluable patients the pooled analysis showed 100% local disease control (15 stable disease, 4 partial responses). Of 26 treated subjects, 8 device-associated adverse events occurred in 7 patients (27%), nearly all resolving within two weeks. The therapy was delivered via a streamlined outpatient EUS-guided procedure. Results were presented from Hadassah Medical Center and support advancement into the ongoing U.S. multicenter IMPACT trial.
Alpha Tau (Nasdaq: DRTS) announced that an abstract titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer” was accepted to the 2026 ASCO Annual Meeting (May 29–June 2, 2026).
The pooled analysis combines safety and efficacy data from 58 patients across three prospective EUS-guided intratumoral Alpha DaRT studies at centers in Montreal and Jerusalem. The abstract will be published on the ASCO website on May 21, 2026 at 5:00 PM ET. Alpha Tau said this acceptance, alongside ASCO GI and DDW presentations, reflects growing scientific interest in its pancreatic program.
Alpha Tau (NASDAQ: DRTS) announced FDA approval of an IDE supplement to expand its U.S. IMPACT pancreatic cancer pilot trial. The supplement adds 10 patients receiving gemcitabine/nab-paclitaxel and increases total trial size from 30 to 40 patients. Recruitment completion shifts from Q2 to Q3 2026 to allow site approvals and added enrollment.
Alpha Tau (Nasdaq: DRTS) announced the first European treatment of a pancreatic cancer patient in the ACAPELLA multicenter trial on April 23, 2026. ACAPELLA tests Alpha DaRT® plus capecitabine for inoperable locally advanced pancreatic ductal adenocarcinoma after mFOLFIRINOX. The procedure occurred at CHU Grenoble Alpes under endoscopic ultrasound guidance. The trial includes an embedded immune biomarker program and runs alongside the U.S. IMPACT pancreatic trial.
Alpha Tau (Nasdaq: DRTS) announced acceptance of the first-ever oral presentation of Alpha DaRT pancreatic cancer clinical results at Digestive Disease Week (DDW) 2026.
The abstract, “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” will be presented May 2, 2026 at 10:30am Central by Dr. Harold Jacob, using combined data from two Hadassah Medical Center protocols. According to the company, these foundational studies informed the IMPACT pilot now enrolling in the U.S. and ongoing planning toward a future pivotal study.
Alpha Tau (Nasdaq: DRTS) announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference on March 18, 2026 from 10:00–10:30 AM ET. The presentation is virtual and Mr. Levy is available for one‑on‑one investor meetings scheduled through Sidoti representatives.
Alpha Tau (NASDAQ: DRTS) reported full-year 2025 results and a corporate update highlighting regulatory, clinical and manufacturing progress. Key items: $76.9M cash, Japanese marketing approval for head and neck cancer, five parallel U.S. trial approvals, positive pancreatic data (ORR 22%/DCR 81%), and a commercial-scale New Hampshire license.
The company reported a $42.6M net loss for 2025 and outlined upcoming recruitment and safety readouts through 2026.
Alpha Tau Medical (Nasdaq: DRTS) received Shonin (MHLW) marketing approval in Japan for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer on Feb 24, 2026.
The approval is the platform's first regulatory clearance outside Israel and requires a post-market surveillance study enrolling 66 patients across five Japanese centers. The company plans discussions on reimbursement and further clinical evaluation with Japanese regulators and clinicians.
Alpha Tau (Nasdaq: DRTS) outlined a busy 2026 with five concurrent U.S. clinical trials, targeted patient‑accrual milestones and planned data readouts across pancreatic cancer, GBM and recurrent cutaneous SCC.
The company reported FDA Modular PMA submissions, a radioactive license for its Hudson, NH manufacturing phase, ongoing manufacturing scale‑up, and extensive IP activity (60+ filings, ~50 grants).
Alpha Tau (Nasdaq: DRTS) reported final results from its first-in-human pancreatic ductal adenocarcinoma (PDAC) study in Montreal, with data presented at ASCO GI 2026 (Jan 8–10, 2026).
Key clinical readouts: 22% objective response rate (ORR) and 81% disease control rate (DCR) across 32 patients (or 23% ORR and 87% DCR excluding the first two low‑dose patients). Immune marker analysis in 23 patients showed no significant worsening of NLR, PLR, CD4/CD8 ratio, or CRP one month post‑treatment, plus a dramatic drop in IL‑6 (p<0.000001), suggesting immune preservation and a potential anti‑inflammatory effect. The company is continuing U.S. multi‑center combination testing in the IMPACT trial (NCT06698458).